Last updated on June 2019

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells


Brief description of study

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.

Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Detailed Study Description

Subjects participating in this study will be followed from time of roll-over from the parent GM T protocol until 15 years after the last GMT infusion, withdrawal of consent, lost to follow-up, or death, whichever occurs first. Both local and central laboratory evaluations and safety assessments will be conducted during this trial. In addition, pediatric subjects will be monitored for growth, development and sexual maturity.

Stage 5 per Tanner Staging Criteria must be reached prior to study discontinuation.

Clinical Study Identifier: NCT03435796

Find a site near you

Start Over

Memorial Sloan Kettering Cancer Center

New York, NY United States
6.76miles
  Connect »

Icahn School of Medicine at Mount Sinai

New York, NY United States
6.97miles
  Connect »

University of Alabama Birmingham

Birmingham, AL United States
7.01miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.